Edward Messing

Professor

University of Rochester Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (1)

Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. A polygenic risk score (PRS) could identify susceptible patients. Methods: A PRS was built using genome-wide association results from the Radiogenomics Consortium ( N = 3,988) and then tested in the prospective REQUITE and URWCI studies ( N = 2,034). The primary outcome was time to patient–reported gross [grade ≥2, (≥G2)] hematuria, analyzed using Cox proportional hazards regression. Secondary outcomes were ≥G2 urinary retention and frequency. The PRS was externally validated for clinically diagnosed irradiation cystitis in the UK Biobank ( N = 8,430). A gene-burden test evaluated rare coding variants. Results: A 115-variant PRS was associated with a significantly increased risk of ≥G2 hematuria [hazard ratio (HR) per SD = 1.22; P = 0.009] as well as urinary retention (HR per SD = 1.18; P = 0.016) and frequency (HR per SD = 1.14; P = 0.036). When binarized, men in the upper decile (PRS high ) had a >2-fold increased risk of hematuria after adjusting for clinical risk factors [HR = 2.12; P = 0.002; Harrel’s concordance index = 0.71 (95% confidence interval, 0.65–0.76)]. A similar effect size was seen in the UK Biobank for clinically diagnosed irradiation cystitis [odds ratio (OR) = 2.15; P = 0.026]. The burden test identified BOD1L1 as a putative novel radiosensitivity gene. Conclusions: This PRS identifies susceptible patients and could guide the selection of those needing reoptimized treatment plans that spare the bladder beyond currently recommended constraints. Impact: PRS-guided treatment planning in radiation oncology could lower the incidence of clinically relevant bladder toxicity and reduce the impact of this outcome on prostate cancer survivors.

Year:

2025

Collaborators (11)

William A. Hall

-

UNITED STATES
View details

Alison Margaret Dunning

University of Cambridge

UNITED KINGDOM
View details

Brian Marples

Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology

University of Rochester Medical Center

UNITED STATES
View details

Harry Ostrer

Professor

Yeshiva University Albert Einstein College of Medicine

UNITED STATES
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Christopher Talbot

Professor of Radiotherapy Genetics

University of Leicester

UNITED KINGDOM
View details

Michelle C. Janelsins

Division Chief and Professor

University of Rochester Medical Center

UNITED STATES
View details

Tiziana Rancati

Researcher

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Ananya Choudhury

The University of Manchester

UNITED KINGDOM
View details

Catharine West

The University of Manchester

UNITED KINGDOM
View details

Sarah Kerns

Associate Professor

Medical College of Wisconsin

UNITED STATES
View details